The Acme Group set out to lead the contract manufacturing industry and become the go-to partner for pharmaceutical firms seeking scalable operations and top-tier skills when it first started operating in 2005.
Over the years, the Acme group has risen to new heights in the pharmaceutical value chain, driven by the founder's vision and purpose. Today, it offers fully integrated contract manufacturing and development solutions to some of the leading pharmaceutical firms in India and around the world.
Acme is a firm believer in rapid expansion along with an emphasis on innovation and customer service. Currently, the group is made up of four cutting-edge, quickly expanding businesses: Acme Formulation, Immacule, Acme Generics Pvt. Ltd., and Veritas Research.
The organization is run by more than 2500 highly qualified employees who produce 17 billion tablets, 3 billion capsules, 30 million ampoules, and 12 million Lyo vials annually in over 500,000 square feet of manufacturing space located throughout Northern India. The group has also branched out into general injectables (liquids and lyophilized), oral hormones (both sex hormones and levothyroxine), and other specialist markets.
Over the last ten years, we have undergone audits and approvals from numerous international regulatory bodies, such as the WHO-Geneva, EU-GMP, TGA Australia, Health Canada, ANVISA, and INVIMA in the UK. In addition, the group has international regulatory licenses in a number of important CIS, Latin American, Asian, and African nations.